For the first time, hepatitis B has a drug that can end the infection for some patients. Chronic hepatitis B is most common among people born in Africa, and the CDC says about two in three people living with it in the United States do not know they have it.
The FDA approved Hibsago (bepirovirsen), made by GSK, on Oct. 20. In two phase 3 trials, 19% of patients who took it for six months reached what doctors call a functional cure: the virus stays under control after treatment stops. None of the patients on a placebo did. Among patients with lower levels of the hepatitis B surface antigen at the start, 26% did.
The CDC puts the chronic hepatitis B rate among foreign-born US residents at 3.1%. For people from Africa it is 8.6%, the highest of any region, ahead of Asia at 5.9%. People born outside the United States are 14% of the population but 69% of those living with chronic hepatitis B. For African immigrant families, this is the disease the new drug was built for.
A cure for people who are already in care
The approval is narrow. Hibsago is for adults without cirrhosis who have taken hepatitis B antivirals for at least six months, whose virus is already suppressed and whose surface antigen is at or below 3,000 IU/mL. In other words, a patient has to be diagnosed, linked to a specialist and on treatment before the new drug is even an option.
That is where the CDC’s number matters. If two in three infected people have never been told, most of them are nowhere near that door. The agency has recommended since 2023 that every adult be tested for hepatitis B at least once in their lifetime. A test that is recommended for everyone still has to be ordered.
Four in five trial patients did not reach a functional cure, and the drug carries a boxed warning for serious liver reactions and low platelet counts. Healio’s report did not give a price.
The pattern is familiar. A breakthrough arrives for a disease that falls hardest on Africa-born patients, and it is open only to those already diagnosed. A cure that reaches only people who were already well served is not a public health win. Screening should be easy to get in the clinics African immigrants use, and GSK should publish its price before the drug reaches a pharmacy.
The FDA approval is dated Oct. 20. The price is still not public.
Have your say